Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 9/20 | 0.52 |
| ▸ | UBE2M | P61081 | 2/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23904810 | 0.88 | UBE2M (0.44) | NR1H4UBE2MDCUN1D1PKMNPSR1 | |
| SCHEMBL21328395 | 0.81 | UBE2M (0.41) | NR1H4UBE2MDCUN1D1NPSR1RXFP1 | |
| SCHEMBL23195620 | 0.79 | CA12 (0.49) | NR1H4CA12CA1CA2CA4 | |
| SCHEMBL5069175 | 0.79 | RAB9A (0.49) | CA12CA1CA2CA4CA6 | |
| SCHEMBL23905239 | 0.79 | ROCK2 (0.40) | NR1H4UBE2MDCUN1D1NPSR1RXFP1 | |
| SCHEMBL19899948 | 0.79 | CA12 (0.49) | NR1H4CA12CA1CA2CA4 | |
| SCHEMBL20554137 | 0.78 | CYP3A4 (0.51) | NR1H4CA12CA1CA2CA4 | |
| SCHEMBL20554083 | 0.78 | ALDH1A1 (0.51) | NR1H4CA12CA1CA2CA4 | |
| SCHEMBL5068352 | 0.77 | SMN1; SMN2 (0.55) | CA12CA1CA2CA4CA6 | |
| SCHEMBL22672569 | 0.76 | CA12 (0.45) | NR1H4CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023200441-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2021198981-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | Janssen Biopharma, Inc. (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | NR1H4 1354/4885UBE2M 2169/4885DCUN1D1 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.